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Background: Assessment of inflammatory activity in patients with ulcerative colitis (UC) is crucial to the prediction
of relapse. Confocal laser endomicroscopy (CLE) is an accurate tool for assessing inflammatory activity in UC
patients. This study aimed to evaluate whether CLE could be used to predict UC relapse reliably.
Methods: In total, forty-three patients with documented UC were analyzed in this study. Patients identified as
having obvious active inflammation by conventional colonoscopy were excluded. The mucosa of each patient’s
sigmoid colon and rectum was assessed by CLE before targeted biopsies were taken. The patients were then
followed up for at least 12 months to evaluate relapse according to the Simple Clinical Colitis Activity Index. The
correlation between CLE classification and UC relapse was evaluated.
Results: Seventeen of 20 patients with histologically confirmed normal or chronic inflammation were diagnosed as
having non-active inflammation by real-time CLE and 22 of 23 patients with histologically confirmed acute
inflammation were diagnosed as having active inflammation by CLE. The sensitivity, specificity, and accuracy of CLE
in real-time diagnosis of active inflammation were 95.7%, 85%, and 90.7%, respectively. The agreement between
CLE and conventional histology was excellent (kappa value = 0.812). Two of 18 (11.1%) patients who were classified
as having non-active inflammation by CLE relapsed, while 16 of 25 (64%) patients classified as having as active
inflammation relapsed. The relapse rate of patients with active inflammation was significantly higher than of those
with non-active inflammation (P < 0.001).
Conclusions: CLE is comparable to conventional histology in predicting relapse in patients with UC.
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Disease duration of ulcerative colitis (UC) is an independ-
ent risk factor for colorectal cancer (CRC) [1]. Since evi-
dence shows that 5-aminosalicylate (5-ASA) can be used
to prevent patients from developing CRC [2], prediction
of relapse is crucial for patients who need prolonged and
strengthened pharmaceutical therapy. Histological evidence
currently suggests that active inflammation and basal
plasmacytosis in colonic biopsies are the most reliable
parameters for prediction of relapse [3]. A recent study by
Bessissow et al. found that the presence of basal plasmacy-
tosis and a Geboes Index (GI) score of ≥3.1 predicted
relapse of UC with normal endoscopy [4].* Correspondence: liyanqing@sdu.edu.cn
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reproduction in any medium, provided the orWith this background, the term “mucosal healing” was
introduced as the goal of UC treatment. Mucosal healing is
thought to be associated with an altered natural history
of UC, including sustained clinical remission, reduced
hospitalization, and surgery [5-7]. As clinical symptoms and
signs are not well correlated with histological mucosal heal-
ing, endoscopic assessment is crucial in the management of
UC, secondary to gold standard histological assessment.
There is currently no validated definition of mucosal
healing with regard to colonoscopy. Limited by its lack
of definition, conventional colonoscopy is sometimes
unreliable for assessing mucosal healing. Although multiple
scoring systems have been applied to the endoscopic assess-
ment of mucosal healing, the applications have been limited
by high inter-observer variability [8]. Reports suggest that
advanced endoscopy, such as magnifying chromoendo-
scopy, is superior to conventional endoscopy in evaluatinghis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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colonoscopy is useful for predicting relapse of patients
with quiescent UC [10]. It can be concluded that assess-
ment would be more accurate if advanced colonoscopy
with higher definition and magnification was used. In
recent years, the optical biopsy instrument confocal
laser endomicroscopy (CLE) has been introduced and
validated for the practice of gastrointestinal endoscopy.
With the capability of a histological level of definition and
magnification, it has proved to be promising in the real-
time assessment of inflammatory activity in UC [11-14].
The aim of this study was to prospectively evaluate
whether the real-time active inflammation assessed by CLE
is related to the higher relapse rate in patients with UC.
Methods
Inclusion and exclusion criteria
Patients with documented UC under colonoscopic sur-
veillance from January 1 to June 31, 2011 were recruited
into this study. Those fulfilling the criteria for clinical
remission of UC according to the Simple Clinical Colitis
Activity Index (SCCAI) were included [15]. The exclusion
criteria were: patients younger than 18 years or older
than 80 years; finding of active inflammation during col-
onoscopy, such as erosion, ulcer, or spontaneous bleed-
ing; poor bowel preparation; cecum intubation failure
due to bowel stricture; unwillingness to participate in
this study; and contraindications to CLE, such as fluor-
escein allergy, hepatic or renal dysfunction, jaundice,
pregnancy and/or breast feeding.
Endoscopic procedures
Bowel preparation before CLE did not differ from that used
for conventional colonoscopy. The CLE device used was an
EC3870K (Pentax, Tokyo, Japan). All patients were given
intravenous injections of 1 ml of 2% fluorescein sodium
(Baiyunshan Mingxing Pharmaceutical, Guangzhou, China)
as an allergy test before procedures were carried out. After
successful cecal intubation, 5 ml of 10% fluorescein sodium
was intravenously injected. The CLE procedure did not
differ from that of conventional colonoscopy, except
for the additional evaluation of mucosal inflammation
in the distal colon, including the sigmoid colon and rectum
by CLE distal laser probe.
Assessment of inflammatory activity by CLE was based
on the previously published four-grade classification, in
which colonic crypts were classified into four grades A, B,
C and D. Types A and B are considered as normal and
chronic inflammation, respectively, and types C and D
indicate acute inflammation. Details of the crypt archi-
tecture classification system are illustrated in Figure 1.
In addition to crypt architecture, fluorescein leakage
into the lumen is also recommended as a marker of
active inflammation. In CLE images of normal colonicmucosa, the lumen of the crypt is free of fluorescein
and appears as a dark center in the crypt; however, in
inflamed mucosa, fluorescein leaks into the crypt lumen;
therefore, the lumen is brighter than the surrounding
epithelium [13].
Histology
Biopsies were taken from the areas of mucosa investi-
gated by CLE. Biopsy specimens were fixed with 10%
formalin and embedded in paraffin, and sections were
stained with hematoxylin and eosin for histopatho-
logical examination. Inflammatory activity was assessed
according to the GI. The GI includes six grades: struc-
tural (architectural changes): chronic inflammatory in-
filtrates: lamina propria neutrophils and eosinophils:
neutrophils in the epithelium: crypt destruction; and
erosion or ulceration. Each grade is divided into 4 or
5 subgroups. The final grades are then divided into
two groups: grades ≤3.0 and >3.0, as grade 3.1 indi-
cates neutrophils in the epithelium, a hallmark of
acute inflammation [16].
Follow-up
All the patients were followed up for 12 months. Each
patient was given copies of a questionnaire containing
SSCAI content in their local language (Chinese). Patients
were required to return the questionnaire each week after
the CLE procedures. According to the published criteria,
a score of 5 or more indicates a UC relapse [17]. Details
of the SSCAI are showed in Table 1.
Statistics
Continuous variables, such as age and disease duration
are presented as mean ± SD. GI score was also calcu-
lated as a continuous variable and presented as the
mean (95% confidence interval [CI]). A one-way analysis
of variance was used to calculate differences between
continuous variables among patients. A chi-square
test was used to evaluate the difference of relapse rate
between groups. Relapse states were evaluated by the
Kaplan–Meier survival curve. A P-value of <0.05 was
taken as significant difference. All the statistical pro-
cesses were run by the SPSS 16.0 program (SPSS Inc.,
Chicago, USA).
Ethical considerations
The colonoscopy and biopsy procedures used in this
study are standard procedures for patients with UC.
The intravenously injected contrast agent fluorescein
sodium is safe and approved for clinical use. All partic-
ipants were informed about the purpose of this study
and asked to give their informed consent. This study was
approved by the Clinical Ethics Committee of Shandong
University Qilu Hospital.
Figure 1 Confocal laser endomicroscopy (CLE) crypt architecture (A, C, E and G) and conventional histology (B, D, F and H). A and B:
CLE image and histology of normal colonic mucosa show regular-shaped and distributed crypts. C and D: CLE image and histology of chronic
inflammation of colonic mucosa show irregular-shaped, distributed but intact crypts. E and F: CLE image and histology show more dilated crypts
with fluorescein leakage into the lumen, with the epithelium disrupted in some crypts. G and H: CLE image and histology show most of the
crypts are disrupted.
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Table 1 The Simple Clinical Colitis Activity Index (SCCAI)
Symptom Score





























Table 2 Demographic and clinical data of patients
Numbers
Recruited 73
Excluded 30 (11 for SSCAI score of ≥5, 17 active
inflammation under white-light endoscopy,
2 failed to return questionnaire)
Included 43
Gender 29 males, 14 females




Therapy 39 with 5-ASA, 2-3 g daily, 4 with SASP,
2 g daily.
5-ASA, 5-aminosalicylic acid; SASP, sulfasalazine; SCCI, Simple Clinical Colitis
Activity Index.
Table 3 CLE vs. histology
CLE grade GI score ≤3 GI score >3 Total
A 9 0 9
B 8 1 9
C 3 17 20
D 0 5 5
Total 20 23 43
GI scores of group C and D were significantly higher than those of group A
and B (P < 0.001), but there was no significant difference between groups A
and B (P = 0.079) or groups C and D (P = 0.514). There was excellent
agreement between real-time CLE and conventional histology (kappa = 0.812).
GI, Geboes Index, CLE, confocal laser endomicroscopy.
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Patients
Seventy-three patients with a documented history of
UC were recruited into this study. Eleven patients
with active inflammation at baseline were excluded
(SCCAI score of 5 or more). Seventeen patients were
excluded during the CLE procedures for active inflamma-
tion under white-light mode (erosion, spontaneous bleed-
ing, and/or clear ulceration). Two patients failed to
return the questionnaire during the follow-up period. In
the end, 43 patients were eligible for analysis (29 males
and 14 females; average age 44 years, range 19-78 years).
The average disease duration was 32.5 months, range
6-72 months. The cecum of all patients was successfully
intubated during the procedures. As maintenance therapy,
39 patients received 5-ASA (Mesalazine, Ethypharm
Industries, France) 2-3 g daily, and 4 patients receivedsulfasalazine (SASP, Jialin Pharmacy, Beijing, China) 2 g
daily. Patient data are given in Table 2.
CLE vs. histology
None of the 9 grade A patients’ histology showed active
inflammation. One of the 9 grade B patient’s GI score
was 4.0. Seventeen of the 20 grade C patients’ GI scores
were more than 3.0. And none of the 5 grade D patients’
GI scores was lower than 3.1. The GI scores of groups C
and D were significantly higher than those of groups A
and B (P < 0.001), but there was no significant difference
between groups A and B (P = 0.079) or group C and D
(P = 0.514). There was excellent agreement between
real-time CLE and conventional histology (kappa = 0.812).
The results were illustrated in Table 3.
Relapse during follow-up
During the follow-up period, a total of 18 patients re-
ported relapses with a SCCAI score of 5 or more. Those
who relapsed were younger (37.4 ± 15.2 vs. 49.1 ± 18.0
[mean ± SD] years, P = 0.031) and had longer duration
(41.1 ± 19.9 vs. 26.2 ± 18.9 [mean ± SD] months, P = 0.017)
than those who remained quiescent (SCCAI score of <5).
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than those who remained quiescent (3.82 ± 0.80 vs.
2.47 ± 0.87) at baseline. Accepting a GI score of >3.0 as
the hallmark of active inflammation, the sensitivity,
specificity, and accuracy of conventional histology in
predicting relapse were 70.6%, 90%, and 79.1%, respectively.
Patients with a GI score of >3.0 at baseline were more likely
to relapse than those with a score of ≤3.0 (16/23 vs. 2/20,Figure 2 Cumulative hazard ratio during the 12-month follow-up. A: C
histology. B: Cumulative hazard of relapse with regard to real-time confocaP < 0.001). The cumulative relapse hazard ratio during the
12-month follow-up is illustrated in Figure 2A with regard
to conventional histology.
For real-time CLE classification, none of 9 grade A
patients, 2 of 9 grade B patients, 11 of 20 grade C patients,
and all 5 grade D patients relapsed during follow-up.
Relapse rates among the four grades were significantly
different (P < 0.001). Accepting grade C and D as activeumulative hazard ratio of relapse with regard to conventional
l laser endomicroscopy.
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of CLE in predicting relapse were 64%, 88.9%, and 74.4%,
respectively. The cumulative relapse hazard ratio during
the 12-month follow-up is illustrated in Figure 2B with
regard to real-time CLE.
Discussion
Treatment of inflammatory bowel disease (IBD) depends
on long-term anti-inflammatory agents, such as 5-ASA,
immunosuppressant and newly developed anti-tumor
necrosis factor agents. The concept of mucosal healing,
which indicates less relapse rate, has been incorporated
into the assessment of patients with UC receiving anti-
inflammatory treatment. However, there is no standard
definition of mucosal healing. Neither endoscopic nor
histological definition has been widely accepted [7].
Studies show that patients with histological evidence
of active inflammation have a higher relapse rate des-
pite their clinical and endoscopic remission [4,18]. Our
study used CLE as the in vivo optical biopsy method to
assess of inflammatory activity and predict relapse for
patients with both clinical and endoscopic remission.
Both in vivo optical and conventional histology identi-
fied a considerable proportion of patients with active
inflammation whose clinical and endoscopic conditions
were quiescent, and these patients were more likely to
relapse during a 6-month follow-up.
Use of CLE in UC mainly focuses on two aspects:
detection of intraepithelial neoplasia [19] and assessment
of inflammatory activity. Previous reports have proved its
accuracy in assessment of inflammatory activity compared
with conventional histology [11-13]. Our previous study
also showed that CLE is superior to conventional white-
light endoscopy in assessing inflammatory activity [13].
Consequently, it is desirable to use CLE to predict relapse
of UC, which may lead to more cost-effective treatment
and surveillance strategies.
Kiesslich et al. were the first to use CLE to evaluate the
relationship between local barrier dysfunction and relapse
in IBD patients. They found that increased epithelial gaps
and fluorescein leakage in the small intestine of IBD
patients were associated with a higher relapse rate, with a
sensitivity of 62.5%, a specificity of 91.2%, and an accuracy
of 79% [20]. Increased gaps in the small intestine of IBD
patients were also identified by probe-based CLE [20].
This study shows that grades C and D have a sensitivity
of 64%, a specificity of 88.9%, and an accuracy of 74.4%
in predicting relapse, which is comparable to the study
of Kiesslich et al. [20].
What are the differences of this study from the previous
ones? First, our study chose the distal colon as a target,
which avoided the influence by terminal ileum intubation
failure (16/135) as previously reported [20]. Second, a
validated four-grade CLE classification was applied inthis study. Compared with the systematic Mainz’s CLE
classification which involves the assessment of crypts,
cell infiltration, and vessels [11], this classification might be
easier to learn for the beginners using CLE. In this study,
the fluorescein leakage into the crypt lumen was incorpo-
rated into the original classification published previously
[13], which indicates local barrier dysfunction.
The limitations of this study are as follows: first, although
all the included patients were both clinically and endo-
scopically quiescent at baseline, assessment of relapse only
depended on clinical assessment. Although the SSCAI
is a validated scoring system, the questionnaire-based
assessment from the patients’ perspective may differ from
the doctor’s assessment, colonoscopy, or histological re-
sults [17]. Second, the duration of follow-up was 6 months,
which is shorter than in previous trials. However, the
predictive value of CLE in this study is similar to trials
with a duration of 12 months [20]. Third, CLE cannot
currently reliably identify different cell types, such as
neutrophils or lymphocytes. Assessment of inflammatory
activity can only be based on indirect parameters, such as
crypt architecture and fluorescein leakage [21]. And finally,
but by no means least, the sample size was small, which
made multifactor analysis difficult, such as the influence of
smoking, maintenance therapy drugs, and diet. Therefore,
the results should be interpreted with caution.Conclusions
In conclusion, inflammatory activity assessment and
prediction of relapse of UC using CLE are accurate com-
pared with conventional histology.
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